FT : Germany’s cabinet approves plan for ‘controlled legalisation’ of cannabis

Germany’s cabinet approves plan for ‘controlled legalisation’ of cannabis
Compromise would allow ‘cannabis clubs’ to grow and distribute marijuana to their members

Germany’s cabinet has approved a plan for “controlled legalisation” of cannabis in a compromise that has upset anti-drug campaigners, pro-legalisation advocates, doctors, judges and the police.

Health minister Karl Lauterbach defended the legislation as a “good law” after the cabinet gave its blessing on Wednesday to a plan whose centrepiece is the creation of “cannabis clubs” that can grow and distribute marijuana to their members.

Lauterbach said the proposal, which must still be approved by the Bundestag, would balance combating drug crime and the rise of increasingly toxic variants on the black market with the need to protect children and young people.

He described it as “controlled legalisation” that marked “an important turning point in a cannabis drug policy that has, unfortunately, failed”.

The measures, due to come into force at the start of next year, represent a sea change in Germany’s drugs policy that could have far-reaching consequences for the rest of the continent. They come at a time when many European nations are closely following experiments with cannabis legalisation in the US and Canada as they grapple with their own approach.

Still, the German law falls far short of a high-profile promise in the 2021 coalition agreement struck by chancellor Olaf Scholz and his coalition partners to allow the “controlled supply of cannabis to adults for recreational purposes in licensed shops”, disappointing supporters of liberalisation and businesses hoping to cash in on a huge new market.

After the idea of a commercial model met resistance from the European Commission, Germany will instead allow the creation of associations that can produce and distribute to members under strict conditions.

Varying limits on the potency and quantity of the drug available to those aged 18 and the over-21s are aimed at limiting the potential damage to young people, who can suffer changes in brain development as a result of cannabis use, as well as an increased risk of psychosis. 

Adults will be able to purchase up to 50g of cannabis a month from the clubs for personal consumption, and will be allowed to cultivate up to three plants at home.

In a second phase, Germany will experiment with allowing limited commercial sales in certain pilot regions.

Lauterbach, a member of Scholz’s Social Democratic (SPD) party has faced sharp criticism over the law from his coalition partners and some professional and medical associations.

The liberal Free Democrats (FDP), which are in government with the SPD and the Greens, have described the 161-page draft law as a “bureaucratic monster” and criticised the upper limits on consumption and possession.

Police and judges have voiced concern about the increased workload they will face as the result of the rules, such as a requirement that no cannabis be consumed within 200 metres of a school, day care centre or playground. “I do hope the federal ministry of health does not think our colleagues will use a folding rule to measure the required 200m distance between a consumer and a nursery,” said Alexander Poitz, deputy chair of the GdP police association, last month.

At the same time, the opposition Christian Democrats (CDU) have claimed the law will result in a “complete loss of control” over drugs, while doctors and pharmacists have expressed anxiety that the reforms will further increase cannabis use and associated health problems among the young.

Lauterbach, a trained doctor who stressed the “very dangerous” impact of cannabis on young people in particular, has promised that a new youth information campaign will accompany the legislation.

Germany’s shift comes as the Czech Republic considers whether to allow cannabis users to cultivate the plant for personal consumption — a change that Luxembourg adopted in June. Malta in 2021 passed a law allowing citizens to possess and grow small amounts of marijuana, while Switzerland in March approved plans to legalise the consumption and sale of cannabis in Zurich as part of a trial project.

The Netherlands, long seen as having the EU’s most liberal drugs policy, has sought to curb drugs tourism while planning to launch pilot schemes to test legalising the sale of the drug — which is still technically criminalised.

REuters : Exclusive: Bridgewater's flagship fund was bearish on US stocks as ral

Exclusive: Bridgewater's flagship fund was bearish on US stocks as rally fizzled
  • * Bridgewater's Pure Alpha most bearish on developed market bonds
  • * Also bearish about the U.S. dollar, metals and stocks
  • * Euro, Singapore dollar were top bullish views
  • * Pure Alpha 12% volatility fund gained 2.5% so far this year

LONDON/NEW YORK, Aug 16 (Reuters) - Bridgewater Associates' flagship fund had a bearish view on U.S. stocks in late July just as a rally that saw the benchmark S&P 500 soar this year was about to lose steam, according to a presentation to investors seen by Reuters.
The July 25 investor briefing, a part of which was seen by Reuters and had not been previously reported, showed the hedge fund founded by legendary investor Ray Dalio was "moderately" bearish on U.S. stocks and Treasuries in its Pure Alpha pool.
Advertisement · Scroll to continue

A continued rally in stocks forced many hedge funds to unwind their bets against equities last month.

The S&P 500 (.SPX) is up 15.6% year-to-date while the Nasdaq 100 (.IXIC) has risen 30.2%, fueled in part by a view that U.S. growth will stay resilient while inflation cools. Both indexes have lost 3.4% and 5.2%, respectively, from their recent highs.

Yields on Treasuries, meanwhile, which move inversely to bond prices, continue to climb. The yield on the 10-year U.S. benchmark Treasury on Tuesday hit 4.274%, its highest since Oct.24.

Rising yields can dull the allure of equities by making bonds look more attractive, while projected company cash flows are also worth less in current dollars when interest rates rise.

Bridgewater, which has $125 billion in assets under management, declined to comment on the presentation about its Pure Alpha fund, which two sources familiar with the matter said was hosted online on July 25. It generally keeps any in-depth views on those assets close to its chest.

The fund had bearish positioning in 15 of the 28 assets it analyzed, including the U.S. dollar, metals and global equities. It was neutral on five categories, such as emerging market currencies and equities, euro zone equities and energy, according to the presentation.

Its top two bullish bets were on the euro and the Singapore dollar, while it was moderately positive about the Mexican peso and inflation-linked bonds.

US BOND MARKET LIQUIDITY
Bridgewater actively bets on the direction of various types of securities — including stocks, bonds, commodities and currencies — by predicting macroeconomic trends.

Greg Jensen, Bridgewater's co-chief investment officer, offered a rare glimpse into some of the fund's views on U.S. asset prices in an Aug. 4 podcast posted on the firm's website. He said that liquidity in the U.S. government bond market was getting worse, as the Treasury increases bond issuance. The higher Treasury issuance is likely to depress asset prices, he added.

Bridgewater's Pure Alpha 12% volatility fund gained 2.5% in the year through Aug. 11, a third source familiar with the matter said, while the Defensive Alpha fund, less dependent on equities, rose 2.1%. Since it was launched in 1991, Pure Alpha 12% has generated 7.7% net total returns annually, according to the same source.

The All Weather strategy, a multi-asset investment approach structured to be indifferent to shifts in economic conditions, was up 3.8% in the same period, the person added.

Macro hedge funds, caught off guard in their rate bets during the banking crisis in March, have seen their performance dip 0.36% on average in the year through July, the latest data from Hedge Fund Research (HFR) shows.

Here are Pure Alpha's views:

>>> Research Calls

Research Calls
  • Upgrades:
    • Brixmor Property (BRX) upgraded to Buy from Neutral at Goldman; tgt $27
    • CareTrust REIT (CTRE) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $24
    • Callon Petroleum (CPE) upgraded to Buy from Neutral at Citigroup; tgt raised to $45
    • Chevron (CVX) upgraded to Buy from Neutral at Mizuho; tgt raised to $209
    • Getty Images (GETY) upgraded to Outperform from In-line at Imperial Capital; tgt $5.75
    • Gulfport Energy (GPOR) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $131
    • Inter & Co (INTR) upgraded to Buy from Neutral at Citigroup; tgt raised to $5.30
    • Keurig Dr Pepper (KDP) upgraded to Buy from Neutral at UBS; tgt raised to $42
    • Matador Resources (MTDR) upgraded to Buy from Neutral at Mizuho; tgt raised to $78
    • NextDecade (NEXT) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $8
    • Magnite (MGNI) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $14
    • Permian Resources (PR) upgraded to Buy from Neutral at Mizuho; tgt raised to $16
    • Pioneer Natural Resources (PXD) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $264
    • SM Energy (SM) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $47
  • Downgrades:
    • CB Financial Service (CBFV) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt $25
    • Chesapeake Energy (CHK) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $96
    • Easterly Government Properties (DEA) downgraded to Underperform from Sector Perform at RBC Capital Mkts; tgt lowered to $13
    • Finance of America (FOA) downgraded to Neutral from Outperform at Credit Suisse; tgt $2
    • Grupo Aval (AVAL) downgraded to Underweight from Neutral at JP Morgan
    • Kimco Realty (KIM) downgraded to Neutral from Buy at Goldman; tgt $21
    • Marqeta (MQ) downgraded to Sell from Neutral at BTIG Research; tgt $4
    • Southland (SLND) downgraded to Neutral from Buy at DA Davidson; tgt lowered to $7
    • Tanger Factory (SKT) downgraded to Neutral from Buy at Goldman; tgt $26
  • Others:
    • GE HealthCare (GEHC) initiated with an Overweight at Wells Fargo; tgt $90
    • Vera Therapeutics (VERA) initiated with a Buy at Guggenheim; tgt $27
    • Viasat (VSAT) resumed with a Neutral at JP Morgan; tgt $35

Reuters - Alibaba’s DingTalk to split from Cloud business group - sources

Alibaba’s DingTalk to split from Cloud business group - sources

SHANGHAI, Aug 16 (Reuters) - Alibaba Group's (9988.HK) work communication and collaboration platform DingTalk will split from the company's cloud division, according to two sources close to the company.

The sources could not confirm the exact timing of the split and also did not confirm news reported by Chinese media outlet Caixin on Wednesday that DingTalk would pursue its own IPO in the near future.

DingTalk will operate as a wholly-owned subsidiary of Alibaba Holding Group and there would be no impact on its services, one source said.

Alibaba's Cloud Intelligence Business Group did not immediately reply to a request for comment on the matter.

Though the Slack-like DingTalk will split structurally from Alibaba's Cloud Business Intelligence unit, the sources said it would continue to work closely with the cloud division technology-wise.

Alibaba's cloud division is itself working towards a public listing, having flagged it would be the first of the Group's newly created six business units to IPO.

The tech giant announced the split of its business in March and has said the cloud division was likely to IPO by May next year.

Alibaba Group last week reported better than expected results for its first quarter, but sales for its Cloud Intelligence Business Group, a major growth driver outside of e-commerce, reported the smallest revenue growth among the group's business units of 4%.

Reporting by Casey Hall; Editing by Himani Sarkar and Conor Humphries

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • COHR -23.1%, MRCY -10% (also names new CEO), JKHY -6.2%, JD -4.6%, EAT -3.8%, A -2.5%, ALC -1.5%
Other news:
  • TSEM -11.3% (Intel (INTC) announces termination of Tower Semiconductor acquisition)
  • HLLY -10.5% (Holley Parent to sell 5.5 mln shares)
  • ARHS -7.9% (stock offering by selling shareholders)
  • HESM -5.7% (prices secondary offering of 10.0 mln Class A shares at $28.80 per share)
  • ACHR -2.7% (stock offering by selling shareholders)
Analyst comments:
  • MQ -6.5% (downgraded to Sell from Neutral at BTIG Research)
  • SKT -2.6% (downgraded to Neutral from Buy at Goldman)
  • FOA -1.8% (downgraded to Neutral from Outperform at Credit Suisse)
  • DEA -1.6% (downgraded to Underperform from Sector Perform at RBC Capital Mkts)
  • KIM -1.1% (downgraded to Neutral from Buy at Goldman)

>>> US Gapping up


Gapping up
In reaction to earnings/guidance
:
  • DLO +30.5% (also names MELI exec as co-CEO, also momentum from Bloomberg report before close that co is considering a sale), CAVA +9.1%, LRN +8.1% (also announces content partnership with Doggyland), HRB +4.5% (also increases dividend by 10%), TJX +3.1%, HOLI +0.8%
Other news:
  • ANGO +9.4% (receives FDA breakthrough device designation for AngioVac System)
  • HHRS +7.3% (plans to redeem public warrants)
  • ANTX +5.6% (prices offering of 7,777,778 shares of its common stock at $9.00 per share)
  • NBTX +3.9% (expiration of HSR waiting period regarding the agreement for worldwide co-development and commercialization of potential first-in-class radioenhancer NBTXR3)
  • COIN +3.6% (secures approval to bring federally regulated crypto futures trading to eligible US customers)
  • AVAL +3.3% (Grupo Aval and Corporación Financiera Colombiana S.A. clarify misinformation circulating in the media)
  • NEXT +3.2% (stock offering by selling shareholders)
  • PBR +2.1% (says news re agreement with Federal Union is unfounded)
  • NVRO +1.9% (New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective Long-Term Relief from Painful Diabetic Neuropathy)
  • IDYA +1.8% (Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma)
  • ALHC +1.5% (CMO and COO Dr. Dinesh Kumar to depart)
  • ELP +1.4% (was notified that GQG Partners acquired a stake of 59,000,000 common shares)
  • REI +1.1% (completed its previously announced acquisition of the Central Basin Platform assets of Founders Oil & Gas IV)
Analyst comments:
  • MGNI +5.6% (upgraded to Outperform from In-line at Evercore ISI)
  • CTRE +1.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)
  • GETY +1.6% (upgraded to Outperform from In-line at Imperial Capital)
  • SM +1.3% (upgraded to Overweight from Neutral at JP Morgan)
  • BRX +1.1% (upgraded to Buy from Neutral at Goldman)
  • PXD +1% (upgraded to Overweight from Neutral at JP Morgan)